The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback